Physician profile
Bryan Stone
NPI 1225095383
$1,856.19
in general payments reported to CMS, 2019-2025
14 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $161 · 2021: $48.28 · 2022: $12.14 · 2023: $650 · 2024: $528 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $7.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.12 |
| Education | $7.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $682.64 | 2021-2025 | Farxiga |
| Amgen INC. | $467.60 | 2020-2024 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $200.56 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $131.23 | 2023 | Terlivaz |
| Ardelyx, INC. | $119.21 | 2024 | Xphozah 30 Mg |
| Baxter Healthcare | $62.40 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.74 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $36.82 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $22.81 | 2023 | Tarpeyo |
| Akebia Therapeutics INC | $21.23 | 2020 | |
| Novo Nordisk INC | $20.78 | 2024 | Ozempic |
| Fresenius USA Marketing, INC. | $16.58 | 2020 | |
| Opko Pharmaceuticals, LLC | $16.45 | 2025 | Rayaldee |
| Vifor Pharma, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.